India's Advinus Therapeutics, a TATA-promoted life sciences research and development company, has announced a new collaboration with Genzyme and Medicines for Malaria Venture (MMV) to develop therapies to address the danger of emerging drug resistance that current anti-malarial treatments face.

The alliance seeks to develop new, improved treatments for specific patient groups most at risk for malaria, particularly pregnant women and infants.

According to a recent study, Malaria kills between 1 - 2 million people annually, with the majority of victims being children under five and pregnant women. Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. It's product and service portfolio is focused on rare disorders, renal disease, orthopaedics, organ transplant, and diagnostic and predictive testing. The company has 400 scientists worldwide working on various research and development projects. Medicines for Malaria Venture (MMV) was established in 1999 as a not-for-profit organization created to discover, develop and deliver safe, effective and affordable anti-malarial drugs through effective public-private partnerships.